These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 20160654

  • 1. Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age.
    Schaefer F, van de Walle J, Zurowska A, Gimpel C, van Hoeck K, Drozdz D, Montini G, Bagdasorova IV, Sorof J, Sugg J, Teng R, Hainer JW, Candesartan in Children with Hypertension Investigators.
    J Hypertens; 2010 May; 28(5):1083-90. PubMed ID: 20160654
    [Abstract] [Full Text] [Related]

  • 2. Candesartan cilexetil: in children and adolescents aged 1 to <17 years with hypertension.
    Hoy SM, Keating GM.
    Am J Cardiovasc Drugs; 2010 May; 10(5):335-42. PubMed ID: 20860416
    [Abstract] [Full Text] [Related]

  • 3. Candesartan cilexetil effectively reduces blood pressure in hypertensive children.
    Franks AM, O'Brien CE, Stowe CD, Wells TG, Gardner SF.
    Ann Pharmacother; 2008 Oct; 42(10):1388-95. PubMed ID: 18664605
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.
    Hübner R, Högemann AM, Sunzel M, Riddell JG.
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S19-25. PubMed ID: 9331000
    [Abstract] [Full Text] [Related]

  • 5. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET.
    Philipp T, Martinez F, Geiger H, Moulin B, Mourad G, Schmieder R, Lièvre M, Heemann U, Legendre C.
    Nephrol Dial Transplant; 2010 Mar; 25(3):967-76. PubMed ID: 19887503
    [Abstract] [Full Text] [Related]

  • 6. Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years.
    Trachtman H, Hainer JW, Sugg J, Teng R, Sorof JM, Radcliffe J, Candesartan in Children with Hypertension (CINCH) Investigators.
    J Clin Hypertens (Greenwich); 2008 Oct; 10(10):743-50. PubMed ID: 19090875
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetic properties and bioequivalence of candesartan cilexetil in Korean healthy volunteers.
    Jeon JY, Im YJ, Kim Y, Han SM, Jo MJ, Shin DH, Yoo JS, Moon BK, Kim BK, Lee BH, Choi YH, Cho BS, Jang HY, Chae SW, Kim MG.
    Drug Dev Ind Pharm; 2013 Sep; 39(9):1296-9. PubMed ID: 23030309
    [Abstract] [Full Text] [Related]

  • 8. Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction.
    Omoto K, Tanabe K, Tokumoto T, Shimmura H, Ishida H, Toma H.
    Transplantation; 2003 Oct 27; 76(8):1170-4. PubMed ID: 14578748
    [Abstract] [Full Text] [Related]

  • 9. Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension.
    Bönner G, Fuchs W.
    Curr Med Res Opin; 2005 Jun 27; 21(6):935-40. PubMed ID: 15969893
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of the effect of candesartan cilexetil on the steady-state pharmacokinetics of tacrolimus in renal transplant patients.
    Pietruck F, Kiel G, Birkel M, Stahlheber-Dilg B, Philipp T.
    Biopharm Drug Dispos; 2005 May 27; 26(4):135-41. PubMed ID: 15768377
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment.
    de Zeeuw D, Remuzzi G, Kirch W.
    J Hum Hypertens; 1997 Sep 27; 11 Suppl 2():S37-42. PubMed ID: 9331004
    [Abstract] [Full Text] [Related]

  • 12. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation.
    Dudhipala N, Veerabrahma K.
    Drug Deliv; 2016 Sep 27; 23(2):395-404. PubMed ID: 24865287
    [Abstract] [Full Text] [Related]

  • 13. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect.
    Elmfeldt D, George M, Hübner R, Olofsson B.
    J Hum Hypertens; 1997 Sep 27; 11 Suppl 2():S49-53. PubMed ID: 9331007
    [Abstract] [Full Text] [Related]

  • 14. Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension.
    Melian EB, Jarvis B.
    Drugs; 2002 Sep 27; 62(5):787-816. PubMed ID: 11929332
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH).
    Palma Gámiz JL, Pêgo M, Contreras EM, Anglada MP, Martínez JO, Esquerra EA, Sagastagoitia Gorostiza JD, Iberian Multicenter Imidapril Study on Hypertension.
    Clin Ther; 2006 Dec 27; 28(12):2040-51. PubMed ID: 17296460
    [Abstract] [Full Text] [Related]

  • 20. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients.
    Fridman K, Andersson OK, Wysocki M, Friberg P, Sunzel M.
    Eur J Clin Pharmacol; 1998 Sep 27; 54(7):497-501. PubMed ID: 9832289
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.